

-continued

```

<210> SEQ ID NO 6
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        His-6-Tag with non-MSP1-42 peptide linker

<400> SEQUENCE: 6

Met Ala His His His His His His Phe Gly Gly Ser Gly Ser Gly Thr
  1           5           10           15

Met

<210> SEQ ID NO 7
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        PCR primer

<400> SEQUENCE: 7

gggtcgggtac catggcagta actccttccg taattgat                               38

<210> SEQ ID NO 8
<211> LENGTH: 48
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        PCR primer

<400> SEQUENCE: 8

ggatcagatg cggccgctta actgcagaaa ataccatcga aaagtgga                               48

<210> SEQ ID NO 9
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        PCR primer

<400> SEQUENCE: 9

taaaaaatat ataaacgaca aac                                               23

<210> SEQ ID NO 10
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        PCR primer

<400> SEQUENCE: 10

aaaagggaag atatttctca ttt                                               23

```

What is claimed is:

1. A method for inducing in a subject an immune response against malaria infection comprising administering to said subject a composition comprising an immunologically effective amount of *P. falciparum* FVO merozoite surface protein-1 (MSP-1₄₂) comprising the sequence set forth in SEQ ID NO:2 that is recombinantly expressed in *E. coli* as a soluble protein that retains its native folding in an acceptable diluent.
2. The method of claim 1 wherein said composition further comprises an adjuvant.
3. The composition of claim 2 wherein said adjuvant is selected from the group consisting of montanide and alum.
4. The composition of claim 2 wherein said adjuvant is ADJUVANT B.
5. A method for inducing a protective immune response to malaria in a mammal, comprising